Discoid lupus erythematosus is the most common form of cutaneous lupus erythematosus. It is more common in women than in men, in individuals between 20 and 40 years of age. It is an inflammatory autoimmune disease in which genetically predisposed individuals are stimulated by hormonal and a variety of exogenous factors including UV radiation, stress, infections, and even temperature changes. Le...

angioedema secondary to c1 inhibitor deficiency has been rarely reported to be associated with systemic lupus erythematosus. a genetic defect of c1 inhibitor produces hereditary angioedema, which is usually presented with cutaneous painless edema, but edema of the genital area, gastrointestinal and laryngeal tracts have also been reported. in lupus patients, angioedema may be the result of an a...

ANA: antinuclear antibody BID: twice a day CLE: cutaneous lupus erythematosus DIL: drug-induced lupus SLE: systemic lupus erythematosus INTRODUCTION Cutaneous lupus erythematosus (CLE), defined as isolated cutaneous lesions without significant systemic involvement, has a reported incidence and prevalence of 4.3 and 73.2 per 100,000, respectively. It occurs more commonly among women with a repor...

Background: Systemic lupus erythematous (SLE) is a multisystemic and autoimmune inflammatory disease characterized by production of autoantibodies against different cellular components. We aimed to investigate children with SLE in terms of clinical symptoms and laboratory findings who referred to Lupus clinic.Materials and Methods: In this cross-sectional study, 36 children with SLE refer...

Patients with systemic lupus erythematosus (SLE) often display clearance deficiencies for various targets like apoptotic cells. Most of the in vitro phagocytosis assays have been performed with leukocyte preparations from patients with SLE and may, therefore, be influenced by immunosuppressive drugs. We isolated circulating hematopoietic stem cells from patients with SLE to generate adherent ce...

tures and functional outcomes. Lupus 1996; 5: 294-9. 8. MOK CC, LAU CS, CHAN YET, WONG RWS: Acute transverse myelopathy in systemic lupus erythematosus: Clinical presentation, treatment and outcome. J Rheumatol 1998; 25: 467-73. 9. OSAWA H, YAMABE H, KAIZUKA M, et al.: Systemic lupus erythematosus associated with transverse myelitis and parkinsonism symptoms. Lupus 1997; 6: 613-5. 10. BAVILE L,...

Podocytopathy in systemic lupus erythematosus is characterised by diffuse foot process effacement without significant peripheral capillary wall immune deposits as seen on electron microscopy. Lupus podocytopathy falls outside the scope of the current International Society of Nephrology and the Renal Pathology Society classification of lupus nephritis. We present a case of relapsing podocytopath...

Accepted 23 October 2012 ABSTRACT Objectives To evaluate treatment with the peptidebased agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. Methods Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have ...